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LETTER TO THE EDITOR
Frequency of serum tumour marker monitoring
Sir - I was particularly interested in the paper by Seckel et
al. on the 'Frequency of Serum Tumour Marker Monitoring
in Patients with Non-Seminomatous Germ Cell Tumours'
which appeared in the June issue. In this paper, the
experienced Charing Cross Group report on observations
made in their patients, including some relapsing whilst on
surveillance following orchidectomy for Stage I non-
seminomatous germ cell tumours. Their main conclusion is
that patients in such watch policies should have their tumour
markers evaluated at weekly intervals rather than monthly
intervals during the first 6 months. They suggest that in this
way those patients at greater risk will demonstrate their
increased risk by a brisker rise in tumour markers.
I thought it might be worthwhile reporting the experience
from five centres in New Zealand in this matter. We have
over 10 years' experience in the watch policy of non-
seminoma germ cell testicular tumour. Our follow up
requisites include monthly tumour marker assessment during
the first year, two monthly assessment during the second year
and three monthly during the third year.
I have recently collated our data, and in our group of 115
patients some 36 have relapsed. Twenty-nine ofthese patients
have relapsed within the first year, including 21 within the
first 6 months, and the remainder have relapsed at varying
intervals with the latest relapse being at 28 months.
Looking more closely at the 21 that relapsed within the
first 6 months, I have found no example of any patient
having marker relapse at a level that would perturb the
Charing Cross Group. The highest beta HCG at relapse was
seen in a patient at 5 months and was 150 IU 1'. The
highest alpha fetoprotein level was 170 g 1-l which was
recorded in a patient relapsing at 2 months. It would appear
from these data that the recommendations made by Seckel et
al. would not have helped us in the management of our
patients as none have relapsed with levels of beta HCG or
alpha fetoprotein that come anywhere near the levels that the
Charing Cross Group would regard as indicative of a poor
prognosis. It would be most interesting to hear the findings
of other groups managing patients in this manner.
B.M. Colls, F.R.C.P., F.R.A.C.P.,
Oncology Service,
Christchurch Hospital,
Christchurch 1
New Zealand.
(On behalf of Oncologists in the five New Zealand Oncology
Centres registering patients in this surveillance study.)
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